Female Sexual Dysfunction: Bremelanotide Phase 3 Program


Source: Palatin Technologies, Inc.
Published: 2014-12-29 - Updated: 2015-01-12
Summary: Palatin Technologies, Inc. has initiated phase 3 reconnect study in the United States for the treatment of female sexual dysfunction.


Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program. The Company has initiated its phase 3 reconnect study in the United States for the treatment of female sexual dysfunction (FSD).

"We are pleased to achieve this major milestone in the bremelanotide program with the initiation of our phase 3 reconnect study in the U.S," stated Carl Spana, Ph.D., President and CEO of Palatin. "This is a key step in our global strategy to bring bremelanotide to market for the millions of women who have FSD and are seeking a safe and effective treatment." Dr. Spana further stated that, "Our recent $30 million financing has provided the financial resources to start the bremelanotide phase 3 pivotal registration program and timing flexibility regarding partnering for the U.S. and other non-European territories."

The start of the reconnect study phase 3 clinical trial in the U.S triggers a development milestone payment of €2.5 million (~$3 million) from Gedeon Richter Plc, Palatin's partner in Europe for bremelanotide for FSD. Palatin is also eligible to receive regulatory and sales milestones, and low double-digit royalties on net sales in the European licensed territory.

Protocol 301 of the reconnect study is a multicenter (~80 sites), randomized, placebo controlled, parallel-group, eight month trial with an open-label extension phase. It is designed to randomize approximately 550 women in North America to evaluate the efficacy and safety of subcutaneous bremelanotide in premenopausal women with hypoactive sexual desire disorder (HSDD) as an on-demand, as-needed treatment. Initial data from the study is anticipated in the middle of calendar year 2016. More information on the trial protocol, including trial design, inclusion/exclusion criteria, etc., can be found at http://clinicaltrials.gov

About Bremelanotide for Female Sexual Dysfunction

Palatin is developing bremelanotide subcutaneous for the treatment of FSD in premenopausal women diagnosed with FSD. Bremelanotide, which is a melanocortin agonist (a compound which binds to a cell receptor and triggers a response) drug candidate, is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone).

About Female Sexual Dysfunction

Female Sexual Dysfunction covers multi-factorial conditions that have anatomical, physiological, medical, psychological and social components. We will seek approval of bremelanotide for the largest category of FSD, hypoactive sexual desire disorder. To establish a diagnosis of FSD, one or more of the disorders making up FSD must be associated with personal distress, as determined by the affected women.i A study of more than 30,000 U.S. women in 2008 reported an age-adjusted point prevalence of sexual difficulties causing personal distress in 12 percent of respondents.ii

There are no drugs in the United States approved for the treatment of FSD. Bremelanotide is an on-demand, as-needed treatment and has the potential to transform the treatment of patients with FSD.

Related Female Sexual Health Information information.

Send us your coming events & LGBT related news stories for publishing on SexualDiversity.org

Full List Here

In July 2017, President Donald Trump announced, "After consultation with my Generals and military experts, please be advised that the United States Government will not accept or allow Transgender individuals to serve in any capacity in the US Military..."


While non-LGBT students struggle most with school classes, exams, and work, their LGBT peers say the biggest problem they face is unaccepting families.


District of Columbia residents can now choose a gender neutral option of their drivers license.


80% of gay and lesbian youth report severe social isolation and 42% of people who are LGBT report living in an unwelcoming environment.


According to the Williams Institute about 46% of those in same-sex relationships have college degrees. This may not sound particularly surprising until you consider that the number for heterosexual couples is close to 30%.


80% of gay and lesbian youth report severe social isolation and 42% of people who are LGBT report living in an unwelcoming environment.

US Gay Population Often Overestimated Which Can Influence Gay Rights Policies


Review of Intersex, DSD Medical and Social Treatment in UK


Women Appear Younger When Eyes, Lips and Eyebrows Stand Out


Cite This Document